- published: 01 Feb 2021
- views: 471
IRAK4
IRAK-4 (interleukin-1 receptor-associated kinase 4), in the IRAK family, is a protein kinase involved in signaling innate immune responses from Toll-like receptors. It also supports signaling from T-cell receptors. IRAK4 contains domain structures which are similar to those of IRAK1, IRAK2, IRAKM and Pelle. IRAK4 is unique compared to IRAK1, IRAK2 and IRAKM in that it functions upstream of the other IRAKs, but is more similar to Pelle in this trait. IRAK4 is important for its clinical applications.
Animals without IRAK-4 are more susceptible to viruses and bacteria but completely resistant to LPS challenge.
History
The first IL-1 receptor-associated kinase (IRAK) was observed in 1994 through experiments with murine T helper cell lines D10N and EL-4. Two years later the first experimental member of this family of kinases, IRAK1, was cloned. In 2002, through database searches at the National Center for Biotechnology Information in an attempt to recognize novel members of the IRAK family, a human cDNA sequence which encoded a peptide sharing significant homology with IRAK1 was identified. This cDNA sequence was found to have five amino acid substitutions compared to IRAK1 and was termed IRAK4.
This page contains text from Wikipedia, the Free Encyclopedia - https://wn.com/IRAK4
Podcasts:
-
Is targeting IRAK4 in patients with lymphoma promising?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Grzegorz Nowakowski, Mayo Clinic, Rochester, US. We asked, Is targeting the interleukin-1 receptor-associated kinase 4 (IRAK4) in patients with lymphoma promising? IRAK4 is essential for signaling downstream of toll‑like receptors, which is critical for the expansion and proliferation of malignant B cells. Nowakowski discusses findings from a phase I study, evaluating a novel IRAK4 oral inhibitor in patients with non-Hodgkin lymphoma.
published: 01 Feb 2021 -
Dr. Garcia-Manero on Targeting IRAK4 in MDS
Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, discusses a phase 1b clinical study that evaluated IRAK1/4 inhibition in patients with low-risk myelodysplastic syndromes that are refractory or resistant to prior therapies. Dr. Garcia-Manero presented information about the study during the 2023 American Society of Clinical Oncology Annual Meeting.
published: 05 Jun 2023 -
irak4
irak4
published: 15 Dec 2008 -
IRAK4 recruitment into the Myddosome
IRAK4 recruitment to clusters of MyD88 (related to Fig. 4). This movie shows an EL4 cell expressing MyD88-GFP (left panel, green channel in merge) and IRAK4-mScarlet interacting with an IL1β-functionalized supported lipid membrane. The movie illustrates the nucleation of MyD88-GFP puncta and the recruitment of IRAK4-mScarlet. Same cell as shown in Fig. 4A. Scale bar, 5 μm. Deliz-Aguirre R, Cao F, Gerpott FH, Auevechanichkul N, Chupanova M, Mun Y, Ziska E, Taylor MJ. On demand MyD88 oligomerization is controlled by IRAK4 during Myddosome signaling. bioRxiv. 2020 Sept 03. https://doi.org/10.1101/2020.09.03.280917
published: 24 Nov 2020 -
Immune Response, Toll Like Receptors (TLR) Pathway - IMGENEX
Watch The second Video in the TLR Series!!!! - Don't for get to Like and Follow! http://youtu.be/d0fgMaQfAQw http://www.imgenex.com Toll Like Receptors: The GateKeepers of Innate Immunity Innate immunity as the first line of defense The innate immune system is an ancient host defense mechanism found in almost every multicellular organism from plants to humans. In invertebrates it is the sole mechanism of defense against pathogens but in higher vertebrates constitutes the first line of defense. The role of the innate immune system is not an insignificant one; not only must it discriminate between self and non-self as well as distinguish between pathogenic and non-pathogenic microbes, it also plays an important role in triggering and optimizing the adaptive immune response. This remarka...
published: 02 May 2011 -
Wild-type, IRAK4 knockout and IRAK1 knockout
MyD88-GFP dynamics in WT, IRAK4 KO and IRAK1 KO EL4 cells (related to Fig. 6). This movie shows MyD88-GFP in WT (left panel), IRAK1 KO (middle panel) and IRAK4 KO EL4 cells lines landing on an IL1β-functionalized supported lipid membrane. White box in each panel indicates example cells shown in Fig. 6A. Scale bar, 5 μm. Deliz-Aguirre R, Cao F, Gerpott FH, Auevechanichkul N, Chupanova M, Mun Y, Ziska E, Taylor MJ. On demand MyD88 oligomerization is controlled by IRAK4 during Myddosome signaling. bioRxiv. 2020 Sept 03. https://doi.org/10.1101/2020.09.03.280917
published: 24 Nov 2020 -
Guillermo Garcia-Manero, MD, on IRAK4, Emavusertib
Guillermo Garcia-Manero, MD, of the Department of Leukemia at MD Anderson Cancer Center, discusses why the novel drug emavusertib is a potential treatment option for patients with hematologic malignancies.
published: 15 Nov 2022 -
090 - Curis Shows Positive Data in AML with First in Class IRAK4 Inhibitor
Curis' CA-4948 is a first-in-class IRAK4 inhibitor that is in clinical development for AML/MDS and NHL. It's estimated that over 50% of AML patients have the IRAK4-L isoform, providing a nice patient population that could be eligible for this therapy. The company provided a recent update in anticipation of the European Hematology Association meeting in early June. They showed 8 out of 9 patients receiving some benefit from the treatment with 4 patients having a strong response (CR or CRi). In this video, I go through the company's clinical programs and evaluate what we can look forward to next. I also touch on $ANVS and $SIOX. Presentation slides: https://drive.google.com/drive/folders/1MENe3kFzFosR6-ALPoY9ovpXXcERH_j3?usp=sharing Help out the show (or join the discord) by becoming a ...
published: 18 May 2021 -
irak4.
irak 4 live
published: 02 Jan 2008
1:42
Is targeting IRAK4 in patients with lymphoma promising?
- Order: Reorder
- Duration: 1:42
- Uploaded Date: 01 Feb 2021
- views: 471
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Grzegorz Nowakowski, Mayo Clinic, Rochester, US. W...
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Grzegorz Nowakowski, Mayo Clinic, Rochester, US. We asked, Is targeting the interleukin-1 receptor-associated kinase 4 (IRAK4) in patients with lymphoma promising?
IRAK4 is essential for signaling downstream of toll‑like receptors, which is critical for the expansion and proliferation of malignant B cells. Nowakowski discusses findings from a phase I study, evaluating a novel IRAK4 oral inhibitor in patients with non-Hodgkin lymphoma.
https://wn.com/Is_Targeting_Irak4_In_Patients_With_Lymphoma_Promising
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Grzegorz Nowakowski, Mayo Clinic, Rochester, US. We asked, Is targeting the interleukin-1 receptor-associated kinase 4 (IRAK4) in patients with lymphoma promising?
IRAK4 is essential for signaling downstream of toll‑like receptors, which is critical for the expansion and proliferation of malignant B cells. Nowakowski discusses findings from a phase I study, evaluating a novel IRAK4 oral inhibitor in patients with non-Hodgkin lymphoma.
2:29
Dr. Garcia-Manero on Targeting IRAK4 in MDS
- Order: Reorder
- Duration: 2:29
- Uploaded Date: 05 Jun 2023
- views: 100
Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, discusses a phase 1b clinical study that evaluated IRAK1/4 inhibition in pat...
Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, discusses a phase 1b clinical study that evaluated IRAK1/4 inhibition in patients with low-risk myelodysplastic syndromes that are refractory or resistant to prior therapies.
Dr. Garcia-Manero presented information about the study during the 2023 American Society of Clinical Oncology Annual Meeting.
https://wn.com/Dr._Garcia_Manero_On_Targeting_Irak4_In_Mds
Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, discusses a phase 1b clinical study that evaluated IRAK1/4 inhibition in patients with low-risk myelodysplastic syndromes that are refractory or resistant to prior therapies.
Dr. Garcia-Manero presented information about the study during the 2023 American Society of Clinical Oncology Annual Meeting.
- published: 05 Jun 2023
- views: 100
3:49
irak4
- Order: Reorder
- Duration: 3:49
- Uploaded Date: 15 Dec 2008
- views: 126
irak4
irak4
https://wn.com/Irak4
irak4
- published: 15 Dec 2008
- views: 126
0:15
IRAK4 recruitment into the Myddosome
- Order: Reorder
- Duration: 0:15
- Uploaded Date: 24 Nov 2020
- views: 132
IRAK4 recruitment to clusters of MyD88 (related to Fig. 4). This movie shows an EL4 cell expressing
MyD88-GFP (left panel, green channel in merge) and IRAK4-mS...
IRAK4 recruitment to clusters of MyD88 (related to Fig. 4). This movie shows an EL4 cell expressing
MyD88-GFP (left panel, green channel in merge) and IRAK4-mScarlet interacting with an IL1β-functionalized supported lipid membrane. The movie illustrates the nucleation of MyD88-GFP puncta and the recruitment of IRAK4-mScarlet. Same cell as shown in Fig. 4A. Scale bar, 5 μm.
Deliz-Aguirre R, Cao F, Gerpott FH, Auevechanichkul N, Chupanova M, Mun Y, Ziska E, Taylor MJ. On demand MyD88 oligomerization is controlled by IRAK4 during Myddosome signaling. bioRxiv. 2020 Sept 03. https://doi.org/10.1101/2020.09.03.280917
https://wn.com/Irak4_Recruitment_Into_The_Myddosome
IRAK4 recruitment to clusters of MyD88 (related to Fig. 4). This movie shows an EL4 cell expressing
MyD88-GFP (left panel, green channel in merge) and IRAK4-mScarlet interacting with an IL1β-functionalized supported lipid membrane. The movie illustrates the nucleation of MyD88-GFP puncta and the recruitment of IRAK4-mScarlet. Same cell as shown in Fig. 4A. Scale bar, 5 μm.
Deliz-Aguirre R, Cao F, Gerpott FH, Auevechanichkul N, Chupanova M, Mun Y, Ziska E, Taylor MJ. On demand MyD88 oligomerization is controlled by IRAK4 during Myddosome signaling. bioRxiv. 2020 Sept 03. https://doi.org/10.1101/2020.09.03.280917
- published: 24 Nov 2020
- views: 132
5:30
Immune Response, Toll Like Receptors (TLR) Pathway - IMGENEX
- Order: Reorder
- Duration: 5:30
- Uploaded Date: 02 May 2011
- views: 1389373
Watch The second Video in the TLR Series!!!! - Don't for get to Like and Follow!
http://youtu.be/d0fgMaQfAQw
http://www.imgenex.com
Toll Like Receptors: The G...
Watch The second Video in the TLR Series!!!! - Don't for get to Like and Follow!
http://youtu.be/d0fgMaQfAQw
http://www.imgenex.com
Toll Like Receptors: The GateKeepers of Innate Immunity
Innate immunity as the first line of defense
The innate immune system is an ancient host defense mechanism found in almost every multicellular organism from plants to humans. In invertebrates it is the sole mechanism of defense against pathogens but in higher vertebrates constitutes the first line of defense. The role of the innate immune system is not an insignificant one; not only must it discriminate between self and non-self as well as distinguish between pathogenic and non-pathogenic microbes, it also plays an important role in triggering and optimizing the adaptive immune response. This remarkable system allows an immediate non-specific response against microorganisms whereas the adaptive immunity mounts a specific response against the invading pathogen during the late phase of the infection.
https://wn.com/Immune_Response,_Toll_Like_Receptors_(Tlr)_Pathway_Imgenex
Watch The second Video in the TLR Series!!!! - Don't for get to Like and Follow!
http://youtu.be/d0fgMaQfAQw
http://www.imgenex.com
Toll Like Receptors: The GateKeepers of Innate Immunity
Innate immunity as the first line of defense
The innate immune system is an ancient host defense mechanism found in almost every multicellular organism from plants to humans. In invertebrates it is the sole mechanism of defense against pathogens but in higher vertebrates constitutes the first line of defense. The role of the innate immune system is not an insignificant one; not only must it discriminate between self and non-self as well as distinguish between pathogenic and non-pathogenic microbes, it also plays an important role in triggering and optimizing the adaptive immune response. This remarkable system allows an immediate non-specific response against microorganisms whereas the adaptive immunity mounts a specific response against the invading pathogen during the late phase of the infection.
- published: 02 May 2011
- views: 1389373
0:16
Wild-type, IRAK4 knockout and IRAK1 knockout
- Order: Reorder
- Duration: 0:16
- Uploaded Date: 24 Nov 2020
- views: 52
MyD88-GFP dynamics in WT, IRAK4 KO and IRAK1 KO EL4 cells (related to Fig. 6). This movie shows MyD88-GFP in WT (left panel), IRAK1 KO (middle panel) and IRAK4 ...
MyD88-GFP dynamics in WT, IRAK4 KO and IRAK1 KO EL4 cells (related to Fig. 6). This movie shows MyD88-GFP in WT (left panel), IRAK1 KO (middle panel) and IRAK4 KO EL4 cells lines landing on an IL1β-functionalized supported lipid membrane. White box in each panel indicates example cells shown in Fig. 6A. Scale bar, 5 μm.
Deliz-Aguirre R, Cao F, Gerpott FH, Auevechanichkul N, Chupanova M, Mun Y, Ziska E, Taylor MJ. On demand MyD88 oligomerization is controlled by IRAK4 during Myddosome signaling. bioRxiv. 2020 Sept 03. https://doi.org/10.1101/2020.09.03.280917
https://wn.com/Wild_Type,_Irak4_Knockout_And_Irak1_Knockout
MyD88-GFP dynamics in WT, IRAK4 KO and IRAK1 KO EL4 cells (related to Fig. 6). This movie shows MyD88-GFP in WT (left panel), IRAK1 KO (middle panel) and IRAK4 KO EL4 cells lines landing on an IL1β-functionalized supported lipid membrane. White box in each panel indicates example cells shown in Fig. 6A. Scale bar, 5 μm.
Deliz-Aguirre R, Cao F, Gerpott FH, Auevechanichkul N, Chupanova M, Mun Y, Ziska E, Taylor MJ. On demand MyD88 oligomerization is controlled by IRAK4 during Myddosome signaling. bioRxiv. 2020 Sept 03. https://doi.org/10.1101/2020.09.03.280917
- published: 24 Nov 2020
- views: 52
7:13
Guillermo Garcia-Manero, MD, on IRAK4, Emavusertib
- Order: Reorder
- Duration: 7:13
- Uploaded Date: 15 Nov 2022
- views: 228
Guillermo Garcia-Manero, MD, of the Department of Leukemia at MD Anderson Cancer Center, discusses why the novel drug emavusertib is a potential treatment optio...
Guillermo Garcia-Manero, MD, of the Department of Leukemia at MD Anderson Cancer Center, discusses why the novel drug emavusertib is a potential treatment option for patients with hematologic malignancies.
https://wn.com/Guillermo_Garcia_Manero,_Md,_On_Irak4,_Emavusertib
Guillermo Garcia-Manero, MD, of the Department of Leukemia at MD Anderson Cancer Center, discusses why the novel drug emavusertib is a potential treatment option for patients with hematologic malignancies.
- published: 15 Nov 2022
- views: 228
52:09
090 - Curis Shows Positive Data in AML with First in Class IRAK4 Inhibitor
- Order: Reorder
- Duration: 52:09
- Uploaded Date: 18 May 2021
- views: 1149
Curis' CA-4948 is a first-in-class IRAK4 inhibitor that is in clinical development for AML/MDS and NHL. It's estimated that over 50% of AML patients have the IR...
Curis' CA-4948 is a first-in-class IRAK4 inhibitor that is in clinical development for AML/MDS and NHL. It's estimated that over 50% of AML patients have the IRAK4-L isoform, providing a nice patient population that could be eligible for this therapy.
The company provided a recent update in anticipation of the European Hematology Association meeting in early June. They showed 8 out of 9 patients receiving some benefit from the treatment with 4 patients having a strong response (CR or CRi).
In this video, I go through the company's clinical programs and evaluate what we can look forward to next.
I also touch on $ANVS and $SIOX.
Presentation slides: https://drive.google.com/drive/folders/1MENe3kFzFosR6-ALPoY9ovpXXcERH_j3?usp=sharing
Help out the show (or join the discord) by becoming a patron at: https://www.patreon.com/breakingbiotech
Follow me on twitter @matthewlepoire
Send me an email matthewlepoire@gmail.com
www.breakingbiotech.com
#breakingbiotech
Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech
https://wn.com/090_Curis_Shows_Positive_Data_In_Aml_With_First_In_Class_Irak4_Inhibitor
Curis' CA-4948 is a first-in-class IRAK4 inhibitor that is in clinical development for AML/MDS and NHL. It's estimated that over 50% of AML patients have the IRAK4-L isoform, providing a nice patient population that could be eligible for this therapy.
The company provided a recent update in anticipation of the European Hematology Association meeting in early June. They showed 8 out of 9 patients receiving some benefit from the treatment with 4 patients having a strong response (CR or CRi).
In this video, I go through the company's clinical programs and evaluate what we can look forward to next.
I also touch on $ANVS and $SIOX.
Presentation slides: https://drive.google.com/drive/folders/1MENe3kFzFosR6-ALPoY9ovpXXcERH_j3?usp=sharing
Help out the show (or join the discord) by becoming a patron at: https://www.patreon.com/breakingbiotech
Follow me on twitter @matthewlepoire
Send me an email matthewlepoire@gmail.com
www.breakingbiotech.com
#breakingbiotech
Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech
- published: 18 May 2021
- views: 1149
3:04
irak4.
- Order: Reorder
- Duration: 3:04
- Uploaded Date: 02 Jan 2008
- views: 101
irak 4 live
irak 4 live
https://wn.com/Irak4.
irak 4 live
- published: 02 Jan 2008
- views: 101
PLAYLIST TIME:
PLAYLIST TIME:
1:42
Is targeting IRAK4 in patients with lymphoma promising?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Ly...
published: 01 Feb 2021
Is targeting IRAK4 in patients with lymphoma promising?
Is targeting IRAK4 in patients with lymphoma promising?
- Report rights infringement
- published: 01 Feb 2021
- views: 471
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Grzegorz Nowakowski, Mayo Clinic, Rochester, US. We asked, Is targeting the interleukin-1 receptor-associated kinase 4 (IRAK4) in patients with lymphoma promising?
IRAK4 is essential for signaling downstream of toll‑like receptors, which is critical for the expansion and proliferation of malignant B cells. Nowakowski discusses findings from a phase I study, evaluating a novel IRAK4 oral inhibitor in patients with non-Hodgkin lymphoma.
2:29
Dr. Garcia-Manero on Targeting IRAK4 in MDS
Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, discus...
published: 05 Jun 2023
Dr. Garcia-Manero on Targeting IRAK4 in MDS
Dr. Garcia-Manero on Targeting IRAK4 in MDS
- Report rights infringement
- published: 05 Jun 2023
- views: 100
Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, discusses a phase 1b clinical study that evaluated IRAK1/4 inhibition in patients with low-risk myelodysplastic syndromes that are refractory or resistant to prior therapies.
Dr. Garcia-Manero presented information about the study during the 2023 American Society of Clinical Oncology Annual Meeting.
0:15
IRAK4 recruitment into the Myddosome
IRAK4 recruitment to clusters of MyD88 (related to Fig. 4). This movie shows an EL4 cell e...
published: 24 Nov 2020
IRAK4 recruitment into the Myddosome
IRAK4 recruitment into the Myddosome
- Report rights infringement
- published: 24 Nov 2020
- views: 132
IRAK4 recruitment to clusters of MyD88 (related to Fig. 4). This movie shows an EL4 cell expressing
MyD88-GFP (left panel, green channel in merge) and IRAK4-mScarlet interacting with an IL1β-functionalized supported lipid membrane. The movie illustrates the nucleation of MyD88-GFP puncta and the recruitment of IRAK4-mScarlet. Same cell as shown in Fig. 4A. Scale bar, 5 μm.
Deliz-Aguirre R, Cao F, Gerpott FH, Auevechanichkul N, Chupanova M, Mun Y, Ziska E, Taylor MJ. On demand MyD88 oligomerization is controlled by IRAK4 during Myddosome signaling. bioRxiv. 2020 Sept 03. https://doi.org/10.1101/2020.09.03.280917
5:30
Immune Response, Toll Like Receptors (TLR) Pathway - IMGENEX
Watch The second Video in the TLR Series!!!! - Don't for get to Like and Follow!
http://y...
published: 02 May 2011
Immune Response, Toll Like Receptors (TLR) Pathway - IMGENEX
Immune Response, Toll Like Receptors (TLR) Pathway - IMGENEX
- Report rights infringement
- published: 02 May 2011
- views: 1389373
Watch The second Video in the TLR Series!!!! - Don't for get to Like and Follow!
http://youtu.be/d0fgMaQfAQw
http://www.imgenex.com
Toll Like Receptors: The GateKeepers of Innate Immunity
Innate immunity as the first line of defense
The innate immune system is an ancient host defense mechanism found in almost every multicellular organism from plants to humans. In invertebrates it is the sole mechanism of defense against pathogens but in higher vertebrates constitutes the first line of defense. The role of the innate immune system is not an insignificant one; not only must it discriminate between self and non-self as well as distinguish between pathogenic and non-pathogenic microbes, it also plays an important role in triggering and optimizing the adaptive immune response. This remarkable system allows an immediate non-specific response against microorganisms whereas the adaptive immunity mounts a specific response against the invading pathogen during the late phase of the infection.
0:16
Wild-type, IRAK4 knockout and IRAK1 knockout
MyD88-GFP dynamics in WT, IRAK4 KO and IRAK1 KO EL4 cells (related to Fig. 6). This movie ...
published: 24 Nov 2020
Wild-type, IRAK4 knockout and IRAK1 knockout
Wild-type, IRAK4 knockout and IRAK1 knockout
- Report rights infringement
- published: 24 Nov 2020
- views: 52
MyD88-GFP dynamics in WT, IRAK4 KO and IRAK1 KO EL4 cells (related to Fig. 6). This movie shows MyD88-GFP in WT (left panel), IRAK1 KO (middle panel) and IRAK4 KO EL4 cells lines landing on an IL1β-functionalized supported lipid membrane. White box in each panel indicates example cells shown in Fig. 6A. Scale bar, 5 μm.
Deliz-Aguirre R, Cao F, Gerpott FH, Auevechanichkul N, Chupanova M, Mun Y, Ziska E, Taylor MJ. On demand MyD88 oligomerization is controlled by IRAK4 during Myddosome signaling. bioRxiv. 2020 Sept 03. https://doi.org/10.1101/2020.09.03.280917
7:13
Guillermo Garcia-Manero, MD, on IRAK4, Emavusertib
Guillermo Garcia-Manero, MD, of the Department of Leukemia at MD Anderson Cancer Center, d...
published: 15 Nov 2022
Guillermo Garcia-Manero, MD, on IRAK4, Emavusertib
Guillermo Garcia-Manero, MD, on IRAK4, Emavusertib
- Report rights infringement
- published: 15 Nov 2022
- views: 228
Guillermo Garcia-Manero, MD, of the Department of Leukemia at MD Anderson Cancer Center, discusses why the novel drug emavusertib is a potential treatment option for patients with hematologic malignancies.
52:09
090 - Curis Shows Positive Data in AML with First in Class IRAK4 Inhibitor
Curis' CA-4948 is a first-in-class IRAK4 inhibitor that is in clinical development for AML...
published: 18 May 2021
090 - Curis Shows Positive Data in AML with First in Class IRAK4 Inhibitor
090 - Curis Shows Positive Data in AML with First in Class IRAK4 Inhibitor
- Report rights infringement
- published: 18 May 2021
- views: 1149
Curis' CA-4948 is a first-in-class IRAK4 inhibitor that is in clinical development for AML/MDS and NHL. It's estimated that over 50% of AML patients have the IRAK4-L isoform, providing a nice patient population that could be eligible for this therapy.
The company provided a recent update in anticipation of the European Hematology Association meeting in early June. They showed 8 out of 9 patients receiving some benefit from the treatment with 4 patients having a strong response (CR or CRi).
In this video, I go through the company's clinical programs and evaluate what we can look forward to next.
I also touch on $ANVS and $SIOX.
Presentation slides: https://drive.google.com/drive/folders/1MENe3kFzFosR6-ALPoY9ovpXXcERH_j3?usp=sharing
Help out the show (or join the discord) by becoming a patron at: https://www.patreon.com/breakingbiotech
Follow me on twitter @matthewlepoire
Send me an email matthewlepoire@gmail.com
www.breakingbiotech.com
#breakingbiotech
Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech
IRAK4
IRAK-4 (interleukin-1 receptor-associated kinase 4), in the IRAK family, is a protein kinase involved in signaling innate immune responses from Toll-like receptors. It also supports signaling from T-cell receptors. IRAK4 contains domain structures which are similar to those of IRAK1, IRAK2, IRAKM and Pelle. IRAK4 is unique compared to IRAK1, IRAK2 and IRAKM in that it functions upstream of the other IRAKs, but is more similar to Pelle in this trait. IRAK4 is important for its clinical applications.
Animals without IRAK-4 are more susceptible to viruses and bacteria but completely resistant to LPS challenge.
History
The first IL-1 receptor-associated kinase (IRAK) was observed in 1994 through experiments with murine T helper cell lines D10N and EL-4. Two years later the first experimental member of this family of kinases, IRAK1, was cloned. In 2002, through database searches at the National Center for Biotechnology Information in an attempt to recognize novel members of the IRAK family, a human cDNA sequence which encoded a peptide sharing significant homology with IRAK1 was identified. This cDNA sequence was found to have five amino acid substitutions compared to IRAK1 and was termed IRAK4.
This page contains text from Wikipedia, the Free Encyclopedia - https://wn.com/IRAK4
Is targeting IRAK4 in patients with lymphoma promi...
Dr. Garcia-Manero on Targeting IRAK4 in MDS...
irak4...
IRAK4 recruitment into the Myddosome...
Immune Response, Toll Like Receptors (TLR) Pathway...
Wild-type, IRAK4 knockout and IRAK1 knockout...
Guillermo Garcia-Manero, MD, on IRAK4, Emavuserti...
090 - Curis Shows Positive Data in AML with First ...
irak4....
-
by Erick E
-
by Arkaik
-
by Arkaik
-
by Arkaik
-
by Arkaik
-
by Arkaik
-
by Arkaik
-
by Arkaik
-
by Arkaik
-
by Arkaik
-
by Arkaik
-
by Arkaik
-
by Arkaik
-
by Arkaik
-
by Arkaik
-
by Arkaik
-
by Arkaik
-
by Arkaik
-
by Arkaik
The Beat Is Rockin'
by: Erick EThe beat is rockin'... (is rockin')
{Refrain:}
The beat is rockin' and never stoppin'
The dj's playing my body's swaying
So keep me staying cause I was saying, oooh boy ...
{Refrain} x2
The beat is rocking and never stoppin' oooh ...
The beat is rockin'(is rockin') x4
{Refrain} x3